Citations

Objective: To determine the impact of modifiable surgical factors on ossiculoplasty outcomes after controlling for ear environment risk. Study Design: Multi-institutional retrospective review. Setting: Six tertiary care centers from 2011 to 2019. Patients Adults and children. Interventions: Ossiculoplasty, including synthetic ossicular replacement prosthesis, autograft interposition, bone cement repair, and mobilization. Main Outcome Measure: Correlation between modifiable surgical factors and pure-tone average air-bone gap (ABG) at most recent audiogram after controlling for preoperative risk using the statistically validated Ear Environment Risk (EER) score. Results: A total of 1,679 cases were included with a median follow-up time of 20 months (IQR, 5–51). After controlling for EER score, malleus engagement of prosthesis yielded favorable ABG versus direct contact to tympanic membrane without malleus engagement (beta = −2.4 dB [−3.8, −1.1], p < 0.001). For total ossicular replacement prostheses (TORP), use of a footplate prosthesis yielded favorable ABG as compared with no footplate prosthesis (−3.6 dB [−6.1, −1.1], p = 0.005). For synthetic prostheses, polyethylene prostheses had a less favorable ABG compared with full titanium or titanium with hydroxyapatite prostheses ( p < 0.05). In cases where the malleus was not engaged in reconstruction, amputation of the malleus head yielded worse ABG (+3.9 dB [1.2, 6.7], p = 0.005). There was no significant difference ( p > 0.05) in ABG for single-stage versus multistaged approach, use of a cartilage cap over the prosthesis versus no cartilage, use of bone cement to secure a PORP to the stapes versus no cement, mastoid cavity obliteration versus no obliteration, and incudostapedial joint reconstruction with joint prosthesis/bone cement versus synthetic PORP. Conclusions: With statistical correction for ear environment risk, several modifiable surgical factors are noted to impact ossiculoplasty hearing outcomes. Level of Evidence: 4.

Abstract Background In the context of competency-based medical education, more research is needed to define point-of-care ultrasound (POCUS) competency and validate learner assessment. To address noted gaps in the currently validated assessment instruments, we developed the Observed Structured POCUS Readiness Examination (OSPRE). The purpose of this study is to demonstrate evidence of validity and reliability of the OSPRE in Physician Assistant (PA) students. Methods A prospective cohort study was designed to demonstrate evidence of validity and reliability for the OSPRE instrument at one PA program. Students completed a hands-on skills assessment utilizing a simulated patient scenario involving a traumatic injury. Student performance was assessed in real time by one reviewer and asynchronously by a second reviewer blinded to the scoring of the initial reviewer. Inter-rater reliability was calculated for overall score and for each criterion of the OSPRE. Results Intraclass correlation coefficient for the final percentage score between the independent reviewers utilizing the OSPRE instrument was noted to be 0.86 (95% CI 0.56–0.95, p < 0.001), demonstrating overall good reliability. Level of agreement for inter-rater reliability for the specific individual criterion ranged between fair and substantial. Conclusion The OSPRE instrument provides a valid and reliable assessment of POCUS skills in PA students. When compared to previously validated assessment instruments, scores on the OSPRE had a wider range, suggesting that the OSPRE might have a greater discriminatory value for POCUS skillset.

Background: Fluorescence in situ hybridization (FISH) is recommended as part of multimodality sampling in the evaluation of biliary strictures, but can be false negative in 40%–50% cases. The aim of this study was to comprehensively assess predictors of false-negative FISH in patients with biliary strictures. Methods: Patients undergoing tissue sampling for biliary strictures from October 20 to February 22 were prospectively enrolled (NCT04572711). Procedural factors such as sampling techniques, order, and utilization of combination sampling were recorded. Results of an optimized pancreatobiliary FISH panel with locus-specific probes for 1q21, 7p12, 8q24, and 9p21 were reported per guidelines. Statistical analyses were performed using BlueSky Statistics v.10.3.1, R package v8.81. Results: Of 327 patients, 93 (28.5%) were diagnosed with malignancy. A false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) was reported in 40 (43.1%) patients. A history of primary sclerosing cholangitis was associated with lower odds of having a false-negative PB-FISH (aOR=0.38, 95% CI=0.16–0.82, p=0.02), whereas a hilar stricture was associated with a significantly higher false-negative PB-FISH in those with cholangiocarcinoma (aOR=3.2 [1.4–7.9], p=0.009). Dilation of biliary strictures prior to brushing was not associated with a lower rate of false-negative PB-FISH. Conclusions: In this prospective study, hilar strictures were more likely to have false-negative PB-FISH. Dilation of strictures did not affect PB-FISH performance. These results can help guide PB-FISH interpretation.

Ultrasound localization microscopy (ULM) enables imaging of the microvasculature at spatial resolutions surpassing the limits of conventional ultrasound, while maintaining comparable penetration depth. This super-resolution technique relies on the localization and tracking of individual microbubbles (MBs) administered into the bloodstream, providing detailed visualization of microvascular structures and functions. However, clinical implementation of ULM faces significant challenges, such as low signal-to-noise ratio (SNR), tissue motion artifacts, and prolonged acquisition times. In this presentation, we will discuss advancements aimed at achieving robust and reproducible clinical implementation of ULM through a series of technical innovations and optimizations. These include signal enhancement techniques to boost MB SNR, advanced algorithms for accurate MB localization and tracking at clinically relevant dosages, optimized data acquisition strategies tailored to clinical workflows, and the development of 3-D imaging capabilities. Through pilot preclinical and clinical studies, we demonstrate the feasibility and efficacy of ULM in various applications, including chronic kidney disease (CKD), kidney transplant, liver disease evaluation, and beyond, in both animal models and human subjects under clinical scanning conditions. These findings underscore the transformative potential of super-resolution ultrasound imaging as a diagnostic tool, paving the way for widespread clinical adoption.

THE 2025 American Society of Clinical Oncology (ASCO) Annual Meeting underscored a key principle: in today’s complex and rapidly evolving cancer landscape, the application of knowledge, not just its acquisition, is our most powerful tool for progress. Robin Zon’s presidential theme, “Driving Knowledge to Action: Building a Better Future,” was brought to life across the plenary sessions and data presentations that spanned tumor types, geographies, and therapeutic modalities. Two dominant motifs emerged from the most practice-changing studies: the use of large-scale, well-designed clinical trials to validate transformative interventions, and a growing effort to repurpose effective therapies earlier in the disease course, challenging historical treatment sequences. These principles reflect the essence of oncology’s future: evidence-powered, patient-centered, and accessible to all.

Abstract Background and Aims Truncating variants in the TTN gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) but also occur as incidental findings in the general population. This study investigated factors associated with the clinical manifestation of TTNtv. Methods An international multicentre retrospective observational study was performed in families with TTNtv-related DCM. Shared frailty models were used to estimate associations of variant characteristics with lifetime risk of DCM, and logistic regression to estimate odds ratios (ORs) for individual-level clinical risk factor profiles (cardiac conditions, cardiovascular comorbidities, lifestyle) and DCM. Results A total of 3158 subjects in 1043 families with TTNtv-related DCM were studied. TTNtv-positive subjects were 21-fold more likely to develop DCM [OR, 21.21; 95% confidence interval (CI), 14.80–30.39]. Disease onset was earlier in males, but was similar for TTNtv of different types and locations. The presence of clinical risk factors was associated with earlier DCM onset (OR, 3.41; 95% CI, 2.06–5.64), with a prior history of atrial fibrillation having a two-fold increased odds of DCM (OR, 2.05; 95% CI, 1.27–3.32). The prevalence of clinical risk factors increased with age; however, the strength of the DCM association was greatest for young-onset (&lt;30 years) disease (OR, 4.75; 95% CI, 2.35–9.60). Administration of beta-adrenergic receptor or renin-angiotensin system-blocking drugs prior to overt DCM was associated with 87% reduced odds of DCM (OR, .13; 95% CI, .08–.23). Conclusions Disease onset in TTNtv-associated familial DCM is dependent on individual patient context and is potentially modifiable by risk factor management and prophylactic therapeutic intervention.

Abstract Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors collected across Lymphoma/Leukemia Molecular Profiling Project sites. Leveraging comparison cohorts of diffuse large B-cell lymphoma, NOS (DLBCL-NOS) and Burkitt lymphoma (BL), and molecular frameworks described in these entities, our analysis revealed a heterogenous molecular landscape, reminiscent of DLBCL-NOS but with an enrichment of BL features. By cell-of-origin classification, 59% were germinal center B-cell–like (GCB), and 25% were activated B-cell–like (ABC). LymphGen, a genetic classifier for DLBCL-NOS, assigned a genetic subtype to 34% of HGBCL-NOS. Although classification rate was lower than in DLBCL-NOS (66%), assigned subtypes spanned the spectrum of LymphGen classes, including 31% of ABCs classified as MCD. Features differentiating HGBCL-NOS from DLBCL-NOS included MYC rearrangement (47% vs 6%); dark zone signature (DZsig) expression (45% vs 7%); and more frequent mutation of ID3, MYC, CCND3, and TP53, all common to BL. A genetic classifier that differentiates DLBCL-NOS from BL classified 53% of DZsig+ tumors as BL-like, and those classified as DLBCL-like were frequently BCL2-rearranged. Among DZsig− GCB tumors, 95% were DLBCL-like. Centralized pathology review reclassified almost half of tumors as DLBCL-NOS but did not identify a more homogenous HGBCL-NOS population, with no difference in features between confirmed and reclassified tumors. In conclusion, molecular testing enables a subset of HGBCL-NOS to be assigned to established categories. Based on rarity and diagnostic challenges, broader inclusion of HGBCL-NOS should be considered in biomarker-driven DLBCL trials.